Sign in
SuspendedPhase 1

Phase I/II clinical trial of autologous hematopoietic stem cell gene therapy in rag1-deficient severe combined immunodeficiency

Key facts

Who runs it
Videja B.V.
Where
Italy, Netherlands, Poland, and Spain4 sites in 4 countriesChoose a country to see its sites
Status
Suspended
Phase
Phase 1
People taking part
6 people, planned
Started
23 Jul 2021
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
19 November 2025

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • RAG1-deficient SCID as confirmed by genetic analysis
  • Peripheral blood T cells < 300/μL and/or naïve T cells < 1/μL
  • Age < 2 years
  • Age at least 8 weeks by the time of busulfan and fludarabine administration
  • Lack of an available HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ) allele-matched (un)related donor)
  • Signed informed consent (parental or guardian)
  • Able to return to the local HSCT centre for follow-up (per protocol) during the 2-year study and the 15-year long-term off study review
  • Absence of peripheral blood naïve CD4+ T cells

Who cannot take part

  • Previous allogeneic HSCT
  • Omenn syndrome
  • Significant organ dysfunction/co-morbidity (including but not limited to): Mechanical ventilation, Shortening fraction on echocardiogram <25%, Renal failure defined as dialysis dependence, uncontrolled seizure disorder.)
  • Any other condition that the investigator considers is a contraindication to collection and/or infusion of transduced cells for that individual or indicate patient's inability to follow the protocol, for example contraindication f to busulfan, major congenital abnormalities, ineligible to receive anaesthesia, or documented refusal or inability of the family to return for scheduled visits
  • Human immunodeficiency virus (HIV) infection or Human T-cell Leukemia Virus (HTLV) infection

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the effect of RAG1 gene therapy on overall survival To evaluate the efficacy of RAG1 gene therapy in achieving reconstitution of the T and B cell immune system in patients with RAG1-SCID at 6 months To evaluate the safety and tolerability of the RAG1 gene therapy product, including identification of short- and long-term adverse events

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
19 November 2025